Ecla Clinic launches advanced laser hair removal service in Dubai
Ecla Clinic, a leading aesthetic and wellness destination in Dubai, is proud to introduce its latest state-of-the-art laser hair removal service, offering a long-term solution for smooth, hair-free skin. Designed for precision, safety, and comfort, this advanced treatment caters to all skin types, providing an effective and virtually painless alternative to traditional hair removal methods.
Utilising FDA-approved laser technology, the new service employs highly concentrated light beams to target and eliminate hair follicles, preventing regrowth while preserving the surrounding skin. The treatment delivers long-lasting results with minimal discomfort, reducing the need for frequent waxing, shaving, or threading.
"At Ecla Clinic, we are dedicated to bringing the latest advancements in aesthetic care to our clients," said the Ecla Clinic team. "Our laser hair removal technology ensures a highly effective, safe, and comfortable experience, allowing our clients to achieve the best possible results in a luxurious, welcoming environment."
Ecla Clinic's approach to laser hair removal is fully personalised. Before starting treatment, clients undergo a comprehensive consultation with expert practitioners who assess skin type, hair density, and medical history to create a bespoke treatment plan.
Each session lasts between 15 and 60 minutes, depending on the treatment area, making it ideal for those with busy schedules. A course of six to eight treatments is typically recommended for long-term hair reduction, as sessions are carefully spaced to target hair follicles during their most active growth phase.
Ecla Clinic's advanced laser system also features built-in cooling technology, enhancing comfort and significantly reducing discomfort during the procedure. Clients receive expert post-treatment guidance on skincare and sun protection to maintain and maximise results.
Ecla Clinic remains a trusted name in aesthetic treatments, combining innovation with expertise to help clients achieve their beauty goals. With a commitment to exceptional care and cutting-edge technology, the clinic is a preferred destination for premium laser hair removal in Dubai.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
31-05-2025
- Al Etihad
US FDA approves Moderna's next-generation COVID vaccine for adults 65 or older
31 May 2025 09:47 (REUTERS)The US Food and Drug Administration (FDA) has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, the company said on Saturday, the first endorsement since the regulator tightened vaccine has also been approved for people aged 12 to 64 with at least one or more underlying risk factors, Moderna said in a said it expects to have the vaccine, called mNEXSPIKE, available for the 2025-2026 respiratory virus season."The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19," CEO Stephane Bancel said in the Department of Health and Human Services, under the leadership of long-time vaccine skeptic Robert F. Kennedy Jr., is increasing regulatory scrutiny on FDA said on May 20 it planned to require drugmakers to test their COVID booster shots against an inert placebo in healthy adults under 65 for approval, effectively limiting them to older adults and those at risk of developing severe Moderna vaccine, branded mNEXSPIKE, can be stored in refrigerators rather than freezers, to offer longer shelf life and make distribution easier, especially in developing countries where supply-chain issues could hamper vaccination Centers for Disease Control and Prevention (CDC), which Kennedy also oversees, said on Thursday that COVID vaccines remain an option for healthy children when parents and doctors agree that it is needed, stopping short of Kennedy's announcement days earlier that the agency would remove the shots from its immunisation CDC announcement eases investor concern to some extent, analysts say, as it keeps the existing framework for older adults and at-risk people who generally seek out the is betting on its newer messenger RNA vaccines as it grapples with waning demand for its original COVID vaccine Spikevax and lower-than-expected uptake of its respiratory syncytial virus approval for mNEXSPIKE was based on late-stage trial data, which showed the shot was not inferior in efficacy compared to Spikevax in individuals aged 12 years and older. The shot also showed superior efficacy compared to Spikevax in adults 18 years of age and older in the study.
Sharjah 24
28-05-2025
- Sharjah 24
US drops COVID vaccine recommendation for pregnant women
Kennedy, FDA commissioner Marty Makary and National Institutes of Health director Jay Bhattacharya said in a video that the shots have been removed from the Centers for Disease Control and Prevention's recommended immunization schedule. The changes come a week after they unveiled tighter requirements for COVID shots, effectively limiting them to older adults and those at risk of developing severe illness. Traditionally, the CDC's Advisory Committee for Immunization Practices would meet and vote on changes to the immunization schedule or recommendations on who should get vaccines before the director of the CDC made a final call. The committee has not voted on these changes. Kennedy, a long-time vaccine skeptic whose department oversees the CDC, has been remaking the U.S. health system to align with President Donald Trump's goal of dramatically shrinking the federal government. "Last year, the Biden Administration urged healthy children to get yet another COVID shot despite the lack of clinical data to support repeat booster strategy in children," Kennedy said in the video. The CDC, following its panel of outside experts, previously recommended updated COVID vaccines for everyone aged six months and older. Insurers said they are reviewing the regulatory guidance to determine their policies, which typically follow the ACIP recommendations.
Gulf Today
26-05-2025
- Gulf Today
Trump's team cited safety in limiting COVID shots
Larry Saltzman has blood cancer. He's also a retired doctor, so he knows getting COVID-19 could be dangerous for him — his underlying illness puts him at high risk of serious complications and death. To avoid getting sick, he stays away from large gatherings, and he's comforted knowing healthy people who get boosters protect him by reducing his exposure to the virus. Until now, that is. Vaccine opponents and skeptics in charge of federal health agencies — starting at the top with Health and Human Services Secretary Robert F. Kennedy Jr. — are restricting access to COVID shots that were a signature accomplishment of President Donald Trump's first term and cost taxpayers about $13 billion to develop, produce, and distribute. The agencies are narrowing vaccination recommendations, pushing drugmakers to perform costly clinical studies, and taking other steps that will result in fewer people getting protection from a virus that still kills hundreds each week in the US. 'There are hundreds of thousands of people who rely on these vaccines,' said Saltzman, 71, of Sacramento, California. 'For people who are immunocompromised, if there aren't enough people vaccinated, we lose the ring that's protecting us. We're totally vulnerable.' The Trump administration on May 20 rolled out tougher approval requirements for COVID shots, described as a COVID-19 'vaccination regulatory framework,' that could leave millions of Americans who want boosters unable to get them. The FDA will encourage new clinical trials on the widely used vaccines before approving them for children and healthy adults. The requirements could cost drugmakers tens of millions of dollars and are likely to leave boosters largely out of reach for hundreds of millions of Americans this fall. Under the new guidance, vaccines will be available for high-risk individuals and seniors. But the FDA will encourage drugmakers to commit to conducting post-marketing clinical trials in healthy adults when the agency approves COVID vaccines for those populations. For the past five years, the shots have been recommended by the Centers for Disease Control and Prevention for everyone 6 months and older. They have been available each fall after being updated to reflect circulating strains of the virus, and the vaccines have been shown to be safe and effective in clinical trials. Vinay Prasad, who leads the FDA's division overseeing vaccines, cited 'distrust of the American public' as he announced the new guidelines at a May 20 briefing. 'We have launched down this multiyear campaign of booster after booster after booster,' he said, adding that 'we do not have gold-standard science to support this for average-risk, low-risk Americans.' The details were outlined in a May 20 article in The New England Journal of Medicine, written by FDA Commissioner Marty Makary. He and Prasad later followed up with the briefing, which appeared the same day on YouTube. The added limits on access aren't the result of any recent data showing there are new health risks from the COVID vaccines. Instead, they reflect a different regulatory stance from Kennedy, who has a history of anti-vaccine activism, and Makary, who has questioned the safety data on COVID mRNA shots. Announcing a major regulatory change in a medical journal and YouTube video is a highly unusual approach that still leaves many questions about implementation unanswered. It remains unclear when the changes will go into effect or whether there will be any public comment period. The changes were announced by the administration before an FDA advisory committee meeting on May 22 to consider the 2026 COVID vaccine formula. It's a sharp reversal from the first Trump administration, which launched Operation Warp Speed — the effort that led to the development of the COVID shots. Trump called the vaccines the 'gold standard' and a 'monumental national achievement.' The announcement is rattling some patient advocacy groups, doctors, nursing home leaders, and researchers who worry about the ramifications. They say higher-risk individuals will be more likely to get COVID if people who aren't at risk don't get boosters that can help reduce transmission. And they say the FDA's restrictions go too far, because they don't provide exceptions for healthy individuals who work in high-risk settings, such as hospitals, who may want a COVID booster for protection. The limits will also make it harder to get insurance coverage for the vaccines. And the FDA's new stance could also increase vaccine hesitancy by undermining confidence in COVID vaccines that have already been subject to rigorous safety review, said Kate Broderick, chief innovation officer at Maravai Life Sciences, which makes mRNA products for use in vaccine development. 'For the public, it raises questions,' she said. 'If someone has concerns, I'd like them to know that of all the vaccines, the ones with the most understood safety profile are probably COVID-19 vaccines. There is an incredible body of data and over 10 billion doses given.' Some doctors and epidemiologists say it could leave healthy people especially vulnerable if more virulent strains of COVID emerge and they can't access COVID shots. 'It's not based on science,' said Rob Davidson, an emergency room doctor in Michigan and executive director of the Committee to Protect Health Care, which works to expand health care access. 'It's what we were all worried would happen. It risks peoples' lives.' Current federal regulators say there is no high-quality evidence showing that vaccinating healthy people, including health workers who are near or around immunocompromised people, provides an additional benefit. 'It is possible, actually, that such approvals and strategies provide false reassurance and lead to increased harms,' Prasad said. The COVID vaccines underwent clinical trials to assess safety, and they have been subject to ongoing surveillance and monitoring since they obtained emergency use authorization from the FDA amid the pandemic. Heart issues and allergic reactions can occur but are rare, according to the CDC. On a separate track, the FDA on May 21 posted letters sent in April to makers of the mRNA COVID vaccines to add information about possible heart injury on warning labels, a move that one former agency official described as overkill. The action came after the Permanent Subcommittee on Investigations, a panel of the Senate Homeland Security and Governmental Affairs Committee, held a hearing on alleged adverse events associated with COVID vaccines. Limiting boosters to healthy people goes against guidance from some medical groups. 'The COVID-19 vaccine is safe, effective, and the best way to protect children,' Sean O'Leary, chair of the Committee on Infectious Diseases at the American Academy of Pediatrics, said in an email. 'Young children under 5 continue to be at the highest risk, with that risk decreasing as they get older.' The COVID booster clampdown is supported by many adherents of the 'Make America Healthy Again' movement, which casts suspicion on traditional medicine. Some opponents of COVID mRNA vaccines say without evidence that the shots cause 'turbo' cancer, are genetic bioweapons, and cause more heart damage than the COVID virus. There is no evidence the shots lead to rapid and aggressive cancers. Cancer rates decreased an average of 1.7% per year for men and 1.3% for women from 2018 to 2022, according to the National Institutes of Health. The COVID vaccines debuted in 2021. Federal regulators say narrowing who can get the boosters will align the U.S. with policies of European nations. But other countries have vastly different economic structures for health care and approaches to preventive care. Many European countries, for example, don't recommend flu shots for the entire population. The US does in part because of the financial drain attributed to lost productivity when people are sick. They also want more information. 'I think there's a void of data,' Makary told CBS News on April 29. 'And I think rather than allow that void to be filled with opinions, I'd like to see some good data.' A massive five-year study on COVID vaccine safety by the Global Vaccine Data Network, involving millions of people, was underway, with about a year left before completion. The Trump administration terminated funding for the project as part of cuts directed by the president's Department of Government Efficiency, and work on the study has stopped for now. There are a multitude of studies, however, on the vaccines' effectiveness in preventing severe illness, hospitalisation, and death.
